- Novo's M&A leader leaves for Forbion; Perrigo CEO's 'personal conduct' issues led to resignationForbion’s portfolio companies have been no stranger to M&A deals in recent years. But the Dutch investment firm now wants more of its biotechs to benefit from the industry’s ...Endpoints · 1mo ago↗ source
- Sciwind has two Western partners for its obesity drug, but is open to moreSciwind Biosciences has already licensed its GLP-1 obesity drug ecnoglutide twice over — to Pfizer and Verdiva Bio — but it is not done yet. The Chinese biotech is seeking new partners for the ri…Endpoints · 1mo ago↗ source
- The seeming inevitability of rising healthcare costsWe’re getting our first signs of where healthcare costs are heading next year. According to a survey of actuaries at 27 health plans covering employers and individuals on the exchanges